Shares of Athersys Inc. (NASDAQ:ATHX) were down 2.3% during mid-day trading on Monday . The stock traded as low as $2.09 and last traded at $2.09, with a volume of 64,856 shares changing hands. The stock had previously closed at $2.14.

Several analysts have recently issued reports on ATHX shares. Maxim Group reiterated a “buy” rating on shares of Athersys in a research report on Monday, June 27th. Zacks Investment Research lowered shares of Athersys from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Finally, TheStreet upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The firm has a market cap of $175.48 million and a PE ratio of 208.00. The firm has a 50-day moving average price of $2.17 and a 200-day moving average price of $2.07.

Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.14. The business earned $15.45 million during the quarter, compared to analysts’ expectations of $1.85 million. During the same quarter last year, the company earned ($0.16) EPS. The firm’s revenue for the quarter was up 2016.4% compared to the same quarter last year. Equities research analysts anticipate that Athersys Inc. will post ($0.23) EPS for the current fiscal year.

In other Athersys news, COO William Lehmann, Jr. sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $2.17, for a total transaction of $54,250.00. Following the completion of the transaction, the chief operating officer now owns 279,017 shares in the company, valued at approximately $605,466.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.